Relation of Maximal Doses of Atorvastatin to Indices of Inflammation, Thrombogenesis and Angiogenesis in High-Risk Patients with Ischemic Heart Disease

2003 ◽  
Vol 104 (s48) ◽  
pp. 9P-9P
Author(s):  
F Marín ◽  
V Roldán ◽  
GJ Caine ◽  
A García-Herola ◽  
V Climent ◽  
...  
Keyword(s):  
Heart Disease ◽  
High Risk ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
High Risk Patients ◽  
Risk Patients

Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease

2005 ◽  
Vol 58 (8) ◽  
pp. 934-940 ◽  
Author(s):  
Antonio Tello ◽  
Francisco Marín ◽  
Vanessa Roldán ◽  
Ana García-Herola ◽  
Sofía Lorenzo ◽  
...  
Keyword(s):  
Heart Disease ◽  
High Risk ◽  
Ischemic Heart Disease ◽  
Maximum Dose ◽  
Ischemic Heart ◽  
High Risk Patients ◽  
Risk Patients

Effects of atorvastatin 80 mg daily on indices of matrix remodelling in ‘high-risk’ patients with ischemic heart disease

2010 ◽  
Vol 139 (1) ◽  
pp. 95-97 ◽  
Author(s):  
Ángel López-Cuenca ◽  
Francisco Marín ◽  
Vanessa Roldán ◽  
Vicente E. Climent ◽  
Mariano Valdés ◽  
...  
Keyword(s):  
Heart Disease ◽  
High Risk ◽  
Ischemic Heart Disease ◽  
Ischemic Heart ◽  
High Risk Patients ◽  
Risk Patients

Dental treatment in very high risk patients with active ischemic heart disease

1993 ◽  
Vol 76 (3) ◽  
pp. 298-300 ◽  
Author(s):  
M. Findler ◽  
D. Galili ◽  
Z. Meidan ◽  
V. Yakirevitch ◽  
A.A. Garfunkel
Keyword(s):  
Heart Disease ◽  
High Risk ◽  
Ischemic Heart Disease ◽  
Dental Treatment ◽  
Ischemic Heart ◽  
High Risk Patients ◽  
Risk Patients ◽  
Very High

scholarly journals Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer

2018 ◽  
Vol 36 (1) ◽  
pp. 44-52 ◽  
Author(s):  
Eric J. Chow ◽  
Yan Chen ◽  
Melissa M. Hudson ◽  
Elizabeth A.M. Feijen ◽  
Leontien C. Kremer ◽  
...  
Keyword(s):  
Heart Disease ◽  
High Risk ◽  
Ischemic Heart Disease ◽  
Childhood Cancer ◽  
Area Under The Curve ◽  
Risk Groups ◽  
Ischemic Heart ◽  
Risk Scores ◽  
Individual Risk ◽  
Survivors Of Childhood Cancer

Purpose We aimed to predict individual risk of ischemic heart disease and stroke in 5-year survivors of childhood cancer. Patients and Methods Participants in the Childhood Cancer Survivor Study (CCSS; n = 13,060) were observed through age 50 years for the development of ischemic heart disease and stroke. Siblings (n = 4,023) established the baseline population risk. Piecewise exponential models with backward selection estimated the relationships between potential predictors and each outcome. The St Jude Lifetime Cohort Study (n = 1,842) and the Emma Children’s Hospital cohort (n = 1,362) were used to validate the CCSS models. Results Ischemic heart disease and stroke occurred in 265 and 295 CCSS participants, respectively. Risk scores based on a standard prediction model that included sex, chemotherapy, and radiotherapy (cranial, neck, and chest) exposures achieved an area under the curve and concordance statistic of 0.70 and 0.70 for ischemic heart disease and 0.63 and 0.66 for stroke, respectively. Validation cohort area under the curve and concordance statistics ranged from 0.66 to 0.67 for ischemic heart disease and 0.68 to 0.72 for stroke. Risk scores were collapsed to form statistically distinct low-, moderate-, and high-risk groups. The cumulative incidences at age 50 years among CCSS low-risk groups were < 5%, compared with approximately 20% for high-risk groups ( P < .001); cumulative incidence was only 1% for siblings ( P < .001 v low-risk survivors). Conclusion Information available to clinicians soon after completion of childhood cancer therapy can predict individual risk for subsequent ischemic heart disease and stroke with reasonable accuracy and discrimination through age 50 years. These models provide a framework on which to base future screening strategies and interventions.

Sign in / Sign up

Export Citation Format

Share Document